Oruka Therapeutics, Inc. clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   Ranging Study of ORKA-002 · Moderate-to-Severe Plaque Psoriasis

   Enrollment closed, study ongoing

   Oruka Therapeutics, Inc.·Phase 2· NCT07474792· Registry history of NCT07474792 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Minor

   ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy…ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose

   Trial completed

   Also in this update: Primary completion date changed from estimate of Jan 2027 to Aug 20, 2026

   Oruka Therapeutics, Inc.·Phase 1· NCT06944379· Registry history of NCT06944379 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

3. Minor

   ORKA-002 Versus Placebo · Moderate-to-Severe Hidradenitis…ORKA-002 Versus Placebo · Moderate-to-Severe Hidradenitis Suppurativa

   Trial sites expanded: 2 → 15 locations

   Also in this update: Start date changed from estimate of Aug 20, 2026 to Aug 21, 2026

   Oruka Therapeutics, Inc.·Phase 2· NCT07783542· Registry history of NCT07783542 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.